| 中文别名 |
6-[2-[4-(2,4-二氯苯基)-5-(4-甲基-1H-咪唑2基)嘧啶2-ylamino]乙基氨基]吡啶-3-腈;6-[[2-[[4-(2,4-二氯苯基)-5-(5-甲基-1H-咪唑-2-基)-2-嘧啶]氨基]乙基]氨基]-3-吡啶甲腈;6-[2-[4-(2,4-二氯苯基)-5-(4-甲基-1H-咪唑-2-基)嘧啶-2-基氨基];6-[2-[4-(2,4-二氯苯基)-5-(4-甲基-1H-咪唑-2-基)嘧啶-2-基氨基]乙基氨基]吡啶-3-甲腈;CHIR-99021 (CT99021) HCl (free base) 抑制剂;CHIR-99021 (CT99021) 抑制剂;抑制剂CHIR-99021;6-[2-[[4-(2,4-二氯苯基)-5-(5-甲基-1H-咪唑-2-基)嘧啶-2-基]氨基]乙氨基]吡啶-3-腈;抑制剂Laduviglusib (CHIR-99021) |
| 英文别名 |
6-[2-[4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-ylamino]ethylamino]pyridine-3-carbonitrile;6-{2-[4-(2,4-Dichloro-phenyl)-5-(4-methyl-1H-imidazol-2-yl)-pyrimidin-2-ylamino]-ethylamino}-nicotinonitrile;CHIR-99021;CT99021;3-Pyridinecarbonitrile, 6-[[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-;4-(4-formyl-3-methoxyphenoxy)butanoicacid;6-(2-(4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-ylamino)ethylamino)nicotinonitrile;6-[2-[[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethylamino]pyridine-3-carbonitrile;CHIR 99021;CHIR99021 (CHIR-99021, CT 99021);CHIR-99021 (CT99021);CHIR-99021 (CT99021) HCl;CHIR-99021 Hydrochloride;3-PYRIDINECARBONITRILE,6-[[2-[[4-(2,4-DICHLOROPHENYL)-5-(5-METHYL-1H-IMIDAZOL-2-YL)-2-PYRIMIDINYL]AMINO]ETHYL]AMINO];CT-99021;6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile;GSK-3 Inhibitor XVI;CHIR99021;CT 99021;6-((2-((4-(2,4-Dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)amino)nicotinonitrile;234CMT4GK4;6-[(2-{[4-(2,4-dichlorophenyl)-5-(4-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile;A;Laduviglusib;Laduviglusib (CHIR-99021);6-[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino]ethylamino]pyridine-3-carbonitrile;BCPP000285;NCGC00250379-01;6-((2-((4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)amino)nicotinonitrile;3-Pyridinecarbonitrile, 6-((2-((4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)-2-pyrimidinyl)amino)ethyl)amino)-;252917-06-9;CCG-269402;CHEMBL412142;C2943;LADUVIGLUSIB [INN];252917-06-9 (free base);TB4423-GMP;AKOS026750421;Laduviglusib (GMP);UNII-234CMT4GK4;6-[(2-{[4-[2,4-Dichlorophenyl)-5-(4-methylimidazol-2-yl)pyrimidin-2-yl]NH}ethyl)NH]pyridine-3-CN;65C;SB19266;GSK-3 Inhibitor XVI - CAS 252917-06-9;GTPL8014;BRD-K16189898-001-04-5;6-[(2-{[4-(2,4-dichlorophenyl)-5-(5-methyl-1H-imidazol-2-yl)pyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile;J-015915;CHIR99021, >=98% (HPLC);6-[2-[[4-(2,4-Dichlorophenyl)-5-(5-methyl-2-imidazolyl)-2-pyrimidinyl]amino]ethylamino]-3-pyridinecarbonitrile;NCGC00250379-03;BDBM50325983;AM81240;3-PYRIDINECARBONITRILE, 6-[[2-[[4-(2,4-DICHLOROPHENYL)-5-(5-METHYL-1H-IMIDAZOL-2-YL)-2-PYRIMIDINYL]AMINO]ETHYL]AMINO]-;CHIR-99021,CT99021;J-518185;Laduviglusib [USAN];AS-16523;BCP01901;HY-10182G;HB1261;FT-0700271;HY-10182;6-[[2-[[4-(2,4-Dichlorophenyl)-5-(5 -methyl-1H-imidazol-2-yl)-2-pyrimidinyl]amino]ethyl]amino]-3-pyridinecarbonitrile;AQGNHMOJWBZFQQ-UHFFFAOYSA-N;6-[(2-{[4-(2,4-dichlorophenyl)-5-(4-methylimidazol-2-yl)-pyrimidin-2-yl]amino}ethyl)amino]pyridine-3-carbonitrile;EX-A535;BRD-K16189898-001-15-1;BRD-K16189898-001-11-0;6-[(2-{[4-(2,4-dichlorophenyl) -5-(4-methylimidazol-2-y... |
